PARIS and SEATTLE, June 29, 2011 /PRNewswire/ -- Cellectis (Alternext: ALCLS), the French genome engineering specialist, announced today the signing of a collaboration agreement with Pregenen, an American biotechnology start-up company dedicated to the creation of innovative tools for genome engineering.
Pregenen is a spinoff from the Northwest Genome Engineering Consortium, a group that brings in renowned international researchers from the Seattle Children's Research Institute, the Fred Hutchinson Cancer Research Center (Seattle) and the University of Washington. This start-up company specializes in the development of new methods for gene repair and innovative approaches in gene therapy.
The collaboration agreement between these two companies will allow them to combine their expertise and technological advances to produce improved high-performance genome engineering tools, most notably meganucleases and advanced meganuclease vector technologies. The agreement also includes the development of meganucleases for use in key therapeutic applications.
"We are very pleased to join our nuclease platform and vectorization technologies with those developed by the Northwest Genome Engineering Consortium," stated Andre Choulika, Chairman and CEO of Cellectis. "Our combined expertise will produce the most advanced genome engineering reagents available."
Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including human therapeutics, bioresearch and agriculture. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris. More information at: www.cellectis.com.
Follow Cellectis on Twitter at www.twitter.com/cellectis
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.